How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Valsartan and Amlodipine Tablets Market
- By Dosage Strength: 80 mg Valsartan / 5 mg Amlodipine, 160 mg Valsartan / 5 mg Amlodipine, 160 mg Valsartan / 10 mg Amlodipine, 320 mg Valsartan / 5 mg Amlodipine, 320 mg Valsartan / 10 mg Amlodipine
- By Formulation Type: Film-coated Tablets, Extended-release Tablets, Immediate-release Tablets
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Distributors
- By Patient Demographics: Adult Hypertension Patients, Elderly Hypertension Patients, Patients with Comorbid Diabetes, Patients with Cardiovascular Disease
- By Therapeutic Application: Hypertension Management, Chronic Heart Failure, Post-Myocardial Infarction Care
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - 80 mg Valsartan / 5 mg Amlodipine leads By Dosage Strength at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Valsartan and Amlodipine Tablets Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Dosage Strength 5
Formulation Type 3
Distribution Channel 4
Patient Demographics 4
Therapeutic Application 3
Companies profiled
Novartis AG
Teva Pharmaceutical Industries Ltd.
Mylan N.V. (Viatris)
Cipla Limited
Sun Pharmaceutical Industries Ltd.
Zydus Cadila
Lupin Limited
Aurobindo Pharma Limited
Torrent Pharmaceuticals Ltd.
Dr. Reddy's Laboratories Ltd.
Sandoz International GmbH
Hetero Drugs Limited
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Mylan N.V. (Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cipla Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sun Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Zydus Cadila
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Lupin Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Aurobindo Pharma Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Torrent Pharmaceuticals Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Dr. Reddy's Laboratories Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sandoz International GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Hetero Drugs Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Alkem Laboratories Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Ipca Laboratories Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Glenmark Pharmaceuticals Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,309M by 2033 · 3.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- 80 mg Valsartan / 5 mg Amlodipine47.9
- 160 mg Valsartan / 5 mg Amlodipine13.9
- 160 mg Valsartan / 10 mg Amlodipine16.9
- 320 mg Valsartan / 5 mg Amlodipine8.6
- 320 mg Valsartan / 10 mg Amlodipine12.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,351M → $1,796M · 3.6%
Europe$941.5M → $1,218M · 3.3%
Asia Pacific$859.6M → $1,149M · 3.7%
Latin America$532.1M → $677.8M · 3.1%
Middle East and Africa$409.3M → $555.5M · 3.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.252026
3.272027
3.292028
3.292029
3.312030
3.312031
3.322032
3.352033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG18.6
- Teva Pharmaceutical Industries Ltd.26.2
- Mylan N.V. (Viatris)7.2
- Cipla Limited8.2
- Sun Pharmaceutical Industries Ltd.5.6
- Zydus Cadila6.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Dosage Strength12.3%
Formulation Type20.9%
Distribution Channel26.4%
Patient Demographics24.3%
Therapeutic Application16.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.3
- Europe22.6
- Asia Pacific21.3
- Latin America12.6
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 74 | 77 | 79 | 97 | 79 | 82 | 81 |
| Teva Pharmaceutical Industries Ltd. | 70 | 73 | 81 | 79 | 90 | 92 | 81 |
| Mylan N.V. (Viatris) | 79 | 82 | 85 | 84 | 73 | 85 | 81 |
| Cipla Limited | 57 | 60 | 77 | 76 | 79 | 64 | 69 |
| Sun Pharmaceutical Industries Ltd. | 59 | 61 | 63 | 61 | 63 | 56 | 61 |
| Zydus Cadila | 66 | 70 | 53 | 71 | 48 | 51 | 60 |
| Lupin Limited | 51 | 54 | 52 | 46 | 50 | 43 | 49 |
| Aurobindo Pharma Limited | 45 | 47 | 44 | 57 | 50 | 52 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V. (Viatris)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Teva Pharmaceutical Industries Ltd. | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Mylan N.V. (Viatris) | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Cipla Limited | − | − | ◐ | ◐ | ◐ | ◐ |
| Sun Pharmaceutical Industries Ltd. | − | ✓ | − | − | ✓ | − |
| Zydus Cadila | − | ◐ | − | ◐ | − | ◐ |
| Lupin Limited | − | − | ◐ | ◐ | ◐ | − |
| Aurobindo Pharma Limited | ◐ | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG81
2Teva Pharmaceutical Industries Ltd.81
3Mylan N.V. (Viatris)81
4Cipla Limited69
5Sun Pharmaceutical Industries Ltd.61
6Zydus Cadila60
7Lupin Limited49
8Aurobindo Pharma Limited49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Novartis AGTeva Pharmaceutical Industries Ltd.Mylan N.V. (Viatris)
Challenger1
Strong scale, closing on the leaders.
Cipla Limited
Contender2
Focused players with pockets of strength.
Sun Pharmaceutical Industries Ltd.Zydus Cadila
Niche2
Specialists in a single segment or region.
Lupin LimitedAurobindo Pharma Limited
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Dosage Strength in North America, then scale across Valsartan and Amlodipine Tablets Market — a $491M beachhead inside a $9.71B market.
Beachhead (SOM)$491Mobtainable near-term
Serviceable (SAM)$3.49Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
80 mg Valsartan / 5 mg Amlodipine
Best fit — highest urgency & budget in Dosage Strength.
Economic buyer77 fit
160 mg Valsartan / 5 mg Amlodipine
Strong fit — clear ROI and a fast path to value.
End user69 fit
160 mg Valsartan / 10 mg Amlodipine
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Dosage Strength in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Formulation Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Distribution Channel
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel26%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Dosage Strength leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Valsartan and Amlodipine Tablets Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation13%
Closed-won6%
$16.8KCAC
$73KLTV
4.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Valsartan and Amlodipine Tablets Market is a high-growth opportunity — $9.12B by 2033, compounding at 10.1%.
TAM · 2025$4.22Btoday
TAM · 2033$9.12Bforecast
CAGR10.1%2027–2033
Cumulative$57.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.12BTotal addressable market
SAM$3.65BServiceable available market
SOM$778MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.1% CAGR
Demand compounds through 2033, outpacing GDP across Dosage Strength.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Dosage Strength moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.12BLarge & growingTAM by 2033 at 10.1% CAGR
$3.65BServiceable nowreachable with today’s model
$778MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.11BBear6.6% CAGR
$9.12BBase10.1% CAGR
$11.7BBull13.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Formulation Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Valsartan and Amlodipine Tablets Market — a $10.5B market by 2033. Plan: grow share from 7.8% to 15.5%.
Market size · 2033$10.5Btotal addressable
Market CAGR9.6%2027–2033
Target share15.5%from 7.8% today
Revenue ambition$1.63Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.8% | 15.5% | At risk |
| Revenue | $854M | $1.63B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 34.9% | 43.7% | Ahead |
| Customer retention | 86.8% | 95.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Dosage Strength
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Formulation Type capability
A defensible second engine — invest in Formulation Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Dosage Strength share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Formulation Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $229M capacity & capability investment
- Greenlight bolt-on M&A in Formulation Type
- Authorise North America expansion plan
- Fund R&D program for Dosage Strength leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Valsartan and Amlodipine Tablets Market conversation — a $7.35B market you can size, segment and defend in minutes.
Market size · 2033$7.35Btotal opportunity
Growth10.4%CAGR to 2033
Addressable buyers1,245+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Dosage Strength
Goal Grow share in Dosage Strength
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 4 mopayback period
$76K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Novartis AGTeva Pharmaceutical Industries Ltd.Mylan N.V. (Viatris)Cipla LimitedSun Pharmaceutical Industries Ltd.Zydus CadilaLupin LimitedAurobindo Pharma Limited+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Valsartan and Amlodipine Tablets Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Valsartan and Amlodipine Tablets Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Valrubicin Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportValproic Acid Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportValley Fever Medication Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportValienamine Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportValganciclovir Hydrochloride Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportValganciclovir Hcl API Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportValganciclovir API Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportValerian Root Supplements Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportValerian Extract Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportValbenazine Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportValbazen Anthelmintic Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportValacyclovir Hydrochloride Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.